Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis

Farr, Morgan A.; Joshi, Tejas P; Lewis, Daniel

doi:10.1080/14728214.2021.2004694

Cited by 4 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Resiquimod is one of the imidazoquinoline derivatives (Dockrella and Kinghorn, 2001), a Toll-like receptor (TLR)-7 and TLR-8 agonist that, like imiquimod ® , belongs to class of imidazoquinolines, small organic molecules with potent antiviral and anticancer activity (Farr et al, 2021). Resiquimod ® (R848) is a potent Toll-like receptor 7, & 8 (TLR7/ 8), agonist for skin lesion treatment with antiviral and antitumor immune responses (Li et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Efficacy of Resiquimod on Treating Chronic Toxoplasmosis in Experimental Infected Mice

BRAKAT,

BADR,

SOLIMAN

et al. 2023

Journal of the Egyptian Society of Parasitology

View full text Add to dashboard Cite

Toxoplasmosis is a zoonotic protozoan infectious disease affects people worldwide with a high rate of morbidity and mortality. The incomplete efficacy of the approved drugs for the chronic Toxoplasma gondii infections endangers one-third of the global humans and animals with reactivation. This is due to the risky complications chronic toxoplasmosis causes.This study evaluated the TLRs 7/8 agonist, Resiquimod ® for treating chronic toxoplasmosis in BALB/c mice infected with the ME49 strain of T. gondii as compared the traditionally used Pyrimethamine ® & Sulphadiazine ® . This was judged by the number of brain cysts, the histpathological degrees in the brain and retina, expression of the apoptotic marker, caspase-3 compared to negative and positive controls.The results showed a statistically significant decrease in the number of brain cysts in resiquimod-treated mice correlated with the histopathological improvement of brain and retina and apoptosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic Efficacy of Resiquimod on Treating Chronic Toxoplasmosis in Experimental Infected Mice

BRAKAT,

BADR,

SOLIMAN

et al. 2023

Journal of the Egyptian Society of Parasitology

View full text Add to dashboard Cite

show abstract

Immunemodulation and Cancer

Liu,

Huang

2023

Anesthesia for Oncological Surgery

View full text Add to dashboard Cite

Comparison of therapeutic agents' short‐term effects on facial and scalp actinic keratosis: A network meta‐analysis

Gupta,

Bamimore,

Wang

et al. 2024

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundCare for actinic keratosis (AK) can be improved with more knowledge on the relative of effect of indicated therapies.ObjectivesUsing network meta‐analyses, we quantitatively determined the comparative “short‐term” effects of interventions in adults with facial and scalp AK.MethodsOn February 28, 2023, evidence from the peer‐reviewed literature was systematically obtained from OVID, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov. We analyzed data from studies published in English, of a trial design, and investigating the effect of an actinic keratosis monotherapy. Patient complete clearance, patient partial clearance or lesion‐specific clearance across adults were analyzed at 8–12 weeks after therapy. Patient complete clearance pertained to proportion of participants who experienced complete clearance of actinic keratosis lesions; patient partial clearance corresponded to percentage of subjects who achieved at least 75% clearance of actinic keratosis lesions; lesion‐specific clearance represented the percentage of all lesions that were cleared. In the main (i.e., base) analyses, nodes were analyzed only at the level of the agent.ResultsData from a total of 84 studies were used—across which 22 active agents were identified. Estimates of interventions' surface under the cumulative ranking curve rankings and (pairwise) relative effects were estimated. Across the three outcomes, fluorouracil 5% was ranked the most effective.ConclusionsOur work is the first to provide information on covariate‐adjusted relative effects of actinic keratosis therapies— including the more recently reported treatments—for the face and scalp; this knowledge may help physicians and patients make more informed decisions.

show abstract

Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis

Cited by 4 publications

References 6 publications

Therapeutic Efficacy of Resiquimod on Treating Chronic Toxoplasmosis in Experimental Infected Mice

Therapeutic Efficacy of Resiquimod on Treating Chronic Toxoplasmosis in Experimental Infected Mice

Immunemodulation and Cancer

Comparison of therapeutic agents' short‐term effects on facial and scalp actinic keratosis: A network meta‐analysis

Contact Info

Product

Resources

About